J&J Unit Under Scrutiny For Alleged Off-Label Marketing
J&J said it was cooperating with the recent subpoena, which it received in June.
This is not the first time the company has come under fire for alleged off-label marketing of the drug.
In December 2003, J&J subsidiary Ortho-McNeil Pharmaceutical Inc. received its first subpoena from the U.S. Attorney’s Office for...
To view the full article, register now.